Pomerantz Law Firm Launches Investigation Into Beta Bionics Due to Investor Claims Pomerantz LLP has begun an investigation regarding potential securities fraud related to Beta Bionics, Inc. This follows a significant stock price drop after disappointing financial results.

Pomerantz Law Firm Launches Investigation Into Beta Bionics Due to Investor Claims #USA #New_York #Pomerantz_LLP #Beta_Bionics #BBNX

Pomerantz Law Firm Launches Investigation into Beta Bionics, Inc. Investors' Claims Pomerantz LLP is investigating potential securities fraud involving Beta Bionics, Inc. following disappointing quarterly results and significant stock price drop.

Pomerantz Law Firm Launches Investigation into Beta Bionics, Inc. Investors' Claims #United_States #New_York #Pomerantz_LLP #Beta_Bionics #BBNX

Beta Bionics to Announce Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026 Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its fourth quarter and full year 2025 financial results after the financial markets close

#BBNX Beta Bionics to Announce Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026

www.stocktitan.net/news/BBNX/beta-bionics-t...

Beta Bionics Announces Preliminary, Unaudited Fourth Quarter 2025 Topline Financial Results and Key Metrics Beta Bionics (Nasdaq: BBNX) reported preliminary, unaudited topline results for Q4 2025, with net sales of at least $32.0 million (up at least 56% vs. $20.4M in Q4 2024). DME channel sales expected at least $22.3 million (up at least 23% YoY) and PBP channel sales expected at least $9.7 million (up at least 308% YoY).The installed customer base is expected to be at least 35,000 users (up at least 128% YoY). New patient starts are expected to be at least 5,581 (up at least 36% YoY), with ~69% converting from MDI, ~25–30% with type 2 diabetes, and a low-30s% share reimbursed through PBP. Fourth quarter and full year 2025 results will be released Feb 17, 2026 with a conference call at 4:30 PM ET.

#BBNX Beta Bionics Announces Preliminary, Unaudited Fourth Quarter 2025 Topline Financial Results and Key Metrics

www.stocktitan.net/news/BBNX/beta-bionics-a...

Beta Bionics (Nasdaq: BBNX) to pre-release Q4 2025 topline results week of Jan. 5 Beta Bionics plans to pre-release topline Q4 2025 net sales and new patient metrics the week of Jan. 5, 2026, with investor meetings Jan. 12–14 in San Francisco.

#BBNX Beta Bionics to Pre-Announce Topline Fourth Quarter 2025 Financial Results the Week of January 5, 2026

www.stocktitan.net/news/BBNX/beta-bionics-t...

Leading Indicators, Thursday December 4, 2025 – Crystal Equity Research

Small-cap stocks with strong volume declines, Thu Dec 4th - #YB #NA #MAMO #LASE #DRMA #CNTX #SYBX #SVCO #PLRX #NDRA #KITT #EKSO #CBIO #BBNX #ZKH #NOAH #GCO #ECVT #BBW - More: crystalequityresearch.com/leading-indi... - #smallcap

Beta Bionics Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Guidance Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter ended September 30, 2025 and raised its full year guidance for the year

#BBNX Beta Bionics Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Guidance

www.stocktitan.net/news/BBNX/beta-bionics-r...

Beta Bionics Reports Second Quarter 2025 Financial Results and Raises Full Year 2025 Guidance Beta Bionics (Nasdaq: BBNX) reported strong Q2 2025 financial results, with net sales reaching $23.2 million, up 54% year-over-year. The company's installed customer base grew 200% to 24,085 users, with 4,934 new patient starts in Q2. The company achieved significant growth in both DME and PBP channels, with PBP channel sales surging 498% to $4.6 million.Key operational metrics showed improvement with gross margin reaching 53.8%. Despite growth, the company reported a net loss of $16.9 million. Beta Bionics raised its full-year 2025 guidance, projecting revenue of $88-93 million, up from previous guidance of $82-87 million.Strategic highlights include securing formulary agreements with major PBMs and completing dosing in the glucagon PK-PD bridging trial for their bihormonal configuration development.

#BBNX Beta Bionics Reports Second Quarter 2025 Financial Results and Raises Full Year 2025 Guidance

www.stocktitan.net/news/BBNX/beta-bionics-r...

Original post on benzinga.com

Sonnet BioTherapeutics Drops 5% Intraday, Rebounds 14% After Hours Amid Delisting Concerns Sonnet BioTherapeutics Holdings Inc. (NASDAQ: SONN) fell 5.54% on Thursday to close at $3.92, before rebou...

#BBNX #benzinga #neuro #Beta #Bionics #Biotech #Biotech […]

[Original post on benzinga.com]

Revolutionary Bionic Pancreas Eliminates Manual Insulin Calculations Through Abbott Partnership First-ever 100% automated insulin delivery system integrates with Abbott's dual glucose-ketone sensor, eliminating manual calculations. See breakthrough details.

#BBNX Beta Bionics Announces Agreement with Abbott to Integrate the iLet Bionic Pancreas with Abbott’s Future Dual Glucose-Ketone Sensor

www.stocktitan.net/news/BBNX/beta-bionics-a...

Beta Bionics Reports First Quarter 2025 Financial Results and Raises Annual Guidance for Full Year 2025 Beta Bionics (BBNX) reported strong Q1 2025 financial results and raised its annual guidance. Net sales reached $17.6 million, up 36% year-over-year, driven by growth in both DME and PBP channels. The company's installed customer base grew 291% to 19,151 users, with 3,853 new patient starts (48% increase). Despite revenue growth, the company reported increased losses with operating loss of $18.6 million and net loss of $28.7 million. Beta Bionics completed an IPO raising $206 million and secured Prime Therapeutics coverage for its iLet Bionic Pancreas. The company raised its 2025 guidance, now expecting revenue of $82-87 million and PBP channel patient starts of 22-25%. The company maintains $295.5 million in cash and investments.

#BBNX Beta Bionics Reports First Quarter 2025 Financial Results and Raises Annual Guidance for Full Year 2025

www.stocktitan.net/news/BBNX/beta-bionics-r...

Beta Bionics Announces Fourth Quarter and Full Year 2024 Financial Results and Introduces Annual Guidance for Full Year 2025 Beta Bionics (NASDAQ: BBNX) reported strong Q4 and full-year 2024 financial results. Q4 net sales reached $20.4M, up 145% YoY, with DME channel sales of $18.1M (+127%) and PBP channel sales of $2.4M (+491%). The installed customer base grew to 15,298 users (+564%).Full-year 2024 showed net sales of $65.1M (+443% YoY), with DME channel sales of $58.8M and PBP channel sales of $6.3M. The company completed an IPO raising $206M and launched the Color iLet Bionic Pancreas with FreeStyle Libre 3 Plus integration.For 2025 guidance, Beta Bionics expects revenue of $80-85M, with over 20% of new patient starts through PBP channel and gross margin of at least 50%. The company ended 2024 with $103.6M in cash and equivalents.

#BBNX Beta Bionics Announces Fourth Quarter and Full Year 2024 Financial Results and Introduces Annual Guidance for Full Year 2025

www.stocktitan.net/news/BBNX/beta-bionics-a...

When Will Beta Bionics Reveal Its 2024 Financial Performance? Key Date Announced Beta Bionics will release Q4 and 2024 financial results on March 25 after market close, followed by a 4:30 PM ET investor conference call and webcast.

#BBNX Beta Bionics to Announce Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025

www.stocktitan.net/news/BBNX/beta-bionics-t...